Marshall Wace
RCUS icon

Marshall Wace’s Arcus Biosciences RCUS Stock Holding History

Marshall Wace’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$81.2M Buy
3,761,437
+373,643
+11% +$8.07M 0.08% 220
2025
Q4 		$80.7M Buy
+3,387,794
New +$69.1M 0.07% 224
2025
Q2 		– Sell
-112,051
Closed -$880K – 3079
2025
Q1 		$880K Buy
+112,051
New +$1.3M ﹤0.01% 1843
2023
Q1 		– Sell
-10,896
Closed -$225K – 3034
2022
Q4 		$225K Sell
10,896
-6,888
-39% -$190K ﹤0.01% 2666
2022
Q3 		$466K Sell
17,784
-210,463
-92% -$5.57M ﹤0.01% 2767
2022
Q2 		$5.78M Buy
228,247
+49,682
+28% +$1.22M 0.01% 1239
2022
Q1 		$5.64M Buy
+178,565
New +$5.98M 0.01% 1273
2021
Q2 		– Sell
-137,283
Closed -$3.85M – 3014
2021
Q1 		$3.85M Sell
137,283
-26,363
-16% -$917K 0.02% 978
2020
Q4 		$4.25M Buy
+163,646
New +$3.96M 0.02% 629
2020
Q2 		– Sell
-2,549
Closed -$35K – 1873
2020
Q1 		$35K Buy
+2,549
New +$31.7K ﹤0.01% 1472
2019
Q1 		– Sell
-23,065
Closed -$249K – 2004
2018
Q4 		$249K Buy
23,065
+5,342
+30% +$62.4K ﹤0.01% 1248
2018
Q3 		$247K Buy
+17,723
New +$226K ﹤0.01% 1036

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace's RCUS Position: Q1 2026 in Review

Marshall Wace increased its Arcus Biosciences (RCUS) stake by 11% in Q1 2026, buying an estimated $8.07M and bringing the position to 3,761,437 shares worth $81.2M. The position accounts for 0.08% of the portfolio, ranked #220.

Marshall Wace first reported a position in RCUS in Q3 2018 and has held it in 12 quarters since. 210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.

  • Marshall Wace held 3,761,437 shares of Arcus Biosciences worth $81.2M as of Q1 2026.
  • Marshall Wace bought 373,643 Arcus Biosciences shares in Q1 2026, an estimated $8.07M.
  • Arcus Biosciences made up 0.08% of Marshall Wace's portfolio in Q1 2026, its #220 holding.
  • Marshall Wace first reported a position in Arcus Biosciences in Q3 2018 and has held it in 12 quarters since.
  • 210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.